Clinical Trials Sponsored by German Adjuvant Breast Cancer Group

Total 323 results

German Breast Group
Roche Pharma AG; Celgene Corporation

Completed

Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) (GeparSepto)

Inflammatory Breast Cancer | HER-2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III | Inflammatory Breast Cancer Stage IV

Germany
German Breast Group
Bristol-Myers Squibb; Pharmacia; Amgen

Completed

Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)

Breast Cancer
Martin-Luther-Universität Halle-Wittenberg
German Breast Group

Unknown

6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients (NNBC3-Europe)

Breast Cancer

Germany
SOLTI Breast Cancer Research Group

Recruiting

Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (RADIOLA)

Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-negative Breast Cancer

Spain
Danish Breast Cancer Cooperative Group

Recruiting

The DBCG Proton Trial: Photon Versus Proton Radiation Therapy for Early Breast Cancer

Early Breast Cancer | Radiation Associated Cardiac Failure

Denmark
Danish Breast Cancer Cooperative Group

Recruiting

Delayed-immediate Versus Delayed Breast Reconstruction in Breast Cancer Patients With Mastectomy and Radiation Therapy

Breast Neoplasm Female | Breast Implant; Complications | Complication of Radiation Therapy

Denmark
SOLTI Breast Cancer Research Group

Terminated

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer (NEREA)

Breast Cancer

Spain, Portugal
Danish Breast Cancer Cooperative Group

Unknown

National Screening in Denmark With MR Versus Mammography and Ultrasound of Women With BRCA1 or BRCA2 Mutations (MR BRCA)

Breast Cancer

Denmark
Korean Breast Cancer Study Group

Unknown

Korean Hereditary Breast Cancer Study (KOHBRA)

Breast Cancer | Ovarian Cancer

Korea, Republic of
Korean Breast Cancer Study Group

Unknown

Assessment of Quality of Life, Bone Density and Safety in Postmenopausal Breast Cancer Patients With Letrozole Therapy

Breast Cancer

Korea, Republic of
Korean Breast Cancer Study Group

Unknown

A Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients With Taxane-Pretreated Recurrent Breast Cancer

Recurrent Breast Cancer

Korea, Republic of
Korean Breast Cancer Study Group

Unknown

Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women (ASTRRA)

Breast Cancer

Korea, Republic of
Spanish Breast Cancer Research Group

Active, not recruiting

Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer (NIKOLE)

Metastatic Breast Cancer

Spain
Spanish Breast Cancer Research Group

Completed

Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer (ChangHER-SC)

Breast Cancer

Spain
SOLTI Breast Cancer Research Group

Completed

SOLTI Breast Cancer Molecular Screening Program (AGATA) (AGATA)

Metastatic Breast Cancer

Spain
Korean Breast Cancer Study Group

Unknown

Neoadjuvant Chemotherapy With Docetaxel and Gemcitabine in Locally Advanced Breast Cancer (NeoTG)

Breast Cancer Stage II | Breast Cancer Stage III

Korea, Republic of
Korean Breast Cancer Study Group

Unknown

Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene (LEXTOP)

Breast Cancer

Korea, Republic of
Korean Breast Cancer Study Group

Unknown

Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients

Metastatic Breast Cancer

Korea, Republic of
SOLTI Breast Cancer Research Group

Not yet recruiting

HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan (ACROSS-TROP2)

Breast Cancer Stage IV

Spain
SOLTI Breast Cancer Research Group

Recruiting

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer (SOLTI-2104)

Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Premenopausal Breast Cancer

Spain
Spanish Breast Cancer Research Group

Recruiting

Registry Study of Pregnancy and Breast Cancer (EMBARCAM)

Breast Cancer and Pregnancy

Spain
SOLTI Breast Cancer Research Group

Completed

Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer (PATRICIA II)

Metastatic Breast Cancer

Spain
SOLTI Breast Cancer Research Group

Terminated

Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC (ARIANNA)

Breast Cancer

Spain
SOLTI Breast Cancer Research Group

Completed

Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer (ONAWA)

Breast Cancer

Spain
SOLTI Breast Cancer Research Group

Completed

Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer (Opti-HER)

Breast Cancer

Spain
Korean Breast Cancer Study Group

Unknown

A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast Cancer (STORM)

Metastatic Breast Cancer | Recurrent Breast Cancer

Korea, Republic of
Korean Breast Cancer Study Group

Unknown

Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women (LETTER)

Breast Cancer

Korea, Republic of
Novartis Pharmaceuticals
Breast International Group; SOLTI Breast Cancer Research Group

Completed

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study (Neo ALTTO)

Neoplasms, Breast

France, Spain, United Kingdom, Belgium, Argentina, Czechia, Germany, Italy, Norway, Russian Federation, Sweden, Taiwan, Hong Kong, Brazil, Hungary, India, Korea, Republic of, Pakistan, Peru, Romania, South Africa, Ukraine, Canada, Lit...
German Breast Group
Pfizer; AMS Advanced Medical Services GmbH

Recruiting

A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). (PADMA)

Metastatic Breast Cancer

Germany
Hoffmann-La Roche
NSABP Foundation Inc; German Breast Group

Active, not recruiting

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Breast Cancer

United States, Italy, United Kingdom, Canada, Czechia, Argentina, Austria, Belgium, Brazil, China, France, Germany, Guatemala, Ireland, Panama, Spain, Sweden, Taiwan, Turkey, Colombia, Hong Kong, Peru, Switzerland, South Africa, Israel, G... and more
Spanish Breast Cancer Research Group
AstraZeneca

Completed

Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (COMETABreast)

Advanced Breast Cancer

Spain
Spanish Breast Cancer Research Group
Sanofi

Completed

Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment

Breast Neoplasms

Spain
Spanish Breast Cancer Research Group
Novartis

Completed

Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients (EDALINE)

Advanced Breast Cancer

Spain
Spanish Breast Cancer Research Group
Novartis

Completed

Pamidronate Administration in Breast Cancer Patients With Bone Metastases

Breast Cancer | Neoplasm Metastasis

Spain
Austrian Breast & Colorectal Cancer Study Group

Completed

Physical Activity for Reduction of Recurrence Rate After Adjuvant Chemotherapy for Localised Colorectal Carcinoma

Colorectal Carcinoma

Austria
Spanish Breast Cancer Research Group
AstraZeneca

Active, not recruiting

Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer (FLIPPER)

Breast Neoplasms

Spain, Ireland
Spanish Breast Cancer Research Group
Sanofi

Completed

Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients

Breast Cancer

Spain
Lund University
Swedish Breast Cancer Group

Completed

No Axillary Surgery for Early Breast Cancer.

Breast Cancer Invasive
Austrian Breast & Colorectal Cancer Study Group

Completed

Randomized Trial on Adjuvant Chemotherapy in Colon Carcinoma Dukes B

Colon Cancer Stage II

Austria
Spanish Breast Cancer Research Group
AstraZeneca

Recruiting

Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab (TRANSCENDER)

Metastatic Breast Cancer | Locally Advanced Breast Cancer

Spain
SOLTI Breast Cancer Research Group
Novartis

Recruiting

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors (ACROPOLI)

Melanoma | Sarcoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Uterine Carcinosarcoma | Mesothelioma | Cholangiocarcinoma | Lung Adenocarcinoma | Triple Negative Breast Cancer | Epithelial Ovarian Cancer | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal... and other conditions

Spain
Spanish Breast Cancer Research Group
Pfizer

Completed

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

Breast Cancer

Spain
Spanish Breast Cancer Research Group
GlaxoSmithKline

Completed

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

Breast Cancer

Spain
Spanish Breast Cancer Research Group
Celgene

Completed

Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer

Breast Cancer

Spain
Spanish Breast Cancer Research Group
Pfizer

Completed

Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients

Breast Cancer

Spain
Austrian Breast & Colorectal Cancer Study Group

Completed

Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients

Early Stage Breast Cancer
SOLTI Breast Cancer Research Group
Novartis

Completed

PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer (PAMELA)

Breast Cancer

Spain
China Breast Cancer Clinical Study Group

Unknown

Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer

Breast Cancer

China
Austrian Breast & Colorectal Cancer Study Group

Terminated

Randomized Study on Neoadjuvant Radio-Chemotherapy in Rectal Carcinoma Dukes B and C

Rectal Cancer Dukes B, Dukes C

Austria
German Breast Group
GlaxoSmithKline; Roche Pharma AG; Teva Pharmaceuticals USA

Completed

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer (GeparSixto)

Inflammatory Breast Cancer | HER-2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III | Inflammatory Breast Cancer Stage IV

Germany

Clinical Trials Sponsored by German Adjuvant Breast Cancer Group

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations